AbbVie's (ABBV) Cariprazine Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. ROIV
2. HUVR:IN
3. TAP
4. DELL
5. LAD
6. ASML
7. NVS
8. TTE
9. ANET
10. NKE

Go back to AbbVie's (ABBV) Cariprazine Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder

AbbVie's Cariprazine (VRAYLAR®) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder

October 29, 2021 7:50 AM EDT

NORTH CHICAGO, Ill., Oct. 29, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced top-line results from two Phase 3 clinical trials, Study 3111-301-001 and Study 3111-302-001, evaluating the efficacy and safety of cariprazine (VRAYLAR®) as an adjunctive treatment for patients with major depressive disorder (MDD). In Study 3111-301-001, cariprazine showed a statistically significant change from baseline to week six in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score compared with placebo. Patients treated with cariprazine at 1.5 mg/day achieved improved MADRS total score at week six compared to placebo (p-value=0.0050). Patients... More